title: Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
abstract: BACKGROUND
  Atrophy is recognized as a measure of destructive changes in multiple sclerosis (MS). The time course and pathologic mechanisms of atrophy development are not well understood. Significant atrophy was reported to occur within 9 to 12 months in relapsing remitting MS.
  
  
  OBJECTIVE
  To test whether atrophy can be detected over short time intervals, and to evaluate its relationship to inflammation.
  
  
  METHODS
  Prior to randomization to a treatment trial, 138 untreated patients with relapsing remitting MS had 3 magnetic resonance imaging scans within a mean +/- SD follow-up of 76 +/- 20.2 days. Brain parenchymal fraction (BPF), a normalized measure of whole brain volume, the proportion of active (gadolinium-enhancing) scans, and the volume of T1-weighted gadolinium-enhancing and T2-weighted hyperintense lesions were determined at all time points. An annualized atrophy rate was estimated by calculating a regression slope.
  
  
  RESULTS
  The median Expanded Disability Status Scale score was 3.5, the mean disease duration was 7.6, and the mean age was 38.5 years. The BPF decreased significantly by -0.229% from scan 1 to scan 3, while the proportion of active scans remained high (65%, 63%, and 67%). The BPF change was only weakly correlated to the volume of T1-weighted gadolinium-enhancing lesions in scan 1 (r = -0.185). The estimated annualized atrophy rate was -1.06% (95% confidence interval, -1.50% to -0.62%).
  
  
  CONCLUSIONS
  The annualized atrophy rate found in this study is comparable with rates reported previously. Measurements of BPF allow detection of atrophy over short time intervals in active disease. The short-term relationship of inflammation to atrophy development was weak. Brain parenchymal fraction might be a promising measure in future phase 2 studies of agents, with an expected effect on tissue-destructive pathologic mechanisms of MS.
authors.affiliation: MS MRI Evaluation Centre Basel, Basel, Switzerland.
authors.forename: Martin
authors.initials: M
authors.lastname: Hardmeier
authors.forename: Stefan
authors.initials: S
authors.lastname: Wagenpfeil
authors.forename: Peter
authors.initials: P
authors.lastname: Freitag
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fisher
authors.forename: Richard A
authors.initials: RA
authors.lastname: Rudick
authors.forename: Mariska
authors.initials: M
authors.lastname: Kooijmans-Coutinho
authors.forename: Michel
authors.initials: M
authors.lastname: Clanet
authors.forename: Ernst W
authors.initials: EW
authors.lastname: Radue
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kappos
mesh_terms: D000328:Adult; D001284:Atrophy; D001921:Brain / Q000473:pathology*; D004185:Disability Evaluation; D005500:Follow-Up Studies; D005682:Gadolinium; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis* / Q000503:physiopathology; D013997:Time Factors
chemical_list: D005682:Gadolinium